Skip to content

Clinical trials

Hematologic Diseases trials

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Hematologic Diseases Clear all

598 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
200015
20017
20023
20038
200410
200514
200610
200713
200815
200919
201017
201117
201214
201315
201427
201521
201614
201734
201824
201924
202032
202139
202230
202332
202429
202519
202621

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed327
Unknown status68
Terminated58
Recruiting57
Active, not recruiting34
Withdrawn21
Not yet recruiting16
Enrolling by invitation11
No longer available4
Suspended1
Approved for marketing1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
National Heart, Lung, and Blood Institute (NHLBI)42
Seagen Inc.30
M.D. Anderson Cancer Center14
National Center for Research Resources (NCRR)12
Novartis Pharmaceuticals11
BioMarin Pharmaceutical8
Emory University7
Nanfang Hospital, Southern Medical University7
Pfizer7
Universitaire Ziekenhuizen KU Leuven7

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Hematologic Diseases598
Neoplasms88
Leukemia63
Anemia, Sickle Cell57
Genetic Diseases, Inborn54
Lymphoma53
Multiple Myeloma52
Anemia48
Hematologic Neoplasms44
Hemorrhagic Disorders43

Trials

Showing 51 to 75 of 598. Each trial links to its page on Pharma Observatory.

498 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.